[2]Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354(9180):716-722.

[3]中国医师协会神经内科医师分会脑血管病专家组. 急性缺血性卒中替奈普酶静脉溶栓治疗中国专家共识. 中国神经精神疾病杂志,2022,48(11):641-651.

[4]Menon BK, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400(10347):161-169.

[5]Muir KW, et al. Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial. Lancet Neurol. 2024;23(11):1087-1096.

[6]Parsons MW, et al. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial. Lancet Neurol. 2024;23(8):775-786.

[7]Meng X, et al. Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial. JAMA. 2024;332(17):1437-1445.

[8]Palaiodimou L, et al. Tenecteplase vs Alteplase in Acute Ischemic Stroke Within 4.5 Hours: A Systematic Review and Meta-Analysis of Randomized Trials. Neurology. 2024;103(9):e209903.

[9]Warach SJ, et al. Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke: The Comparative Effectiveness of Routine Tenecteplase vs Alteplase in Acute Ischemic Stroke (CERTAIN) Collaboration. JAMA Neurol. 2023;80(7):732-738.

[10]Rousseau JF, et al. Short-Term Safety and Effectiveness for Tenecteplase and Alteplase in Acute Ischemic Stroke. JAMA Netw Open. 2025;8(3):e250548.